Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

2.

First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors.

Schultheis B, Strumberg D, Santel A, Vank C, Gebhardt F, Keil O, Lange C, Giese K, Kaufmann J, Khan M, Drevs J.

J Clin Oncol. 2014 Dec 20;32(36):4141-8. doi: 10.1200/JCO.2013.55.0376. Epub 2014 Nov 17.

PMID:
25403217
3.

A phase I trial assessing the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics of single-dose Auron Misheil therapy in healthy male subjects.

Scheele J, Diergarten K, Drevs J, Niazi FR.

J Clin Pharm Ther. 2013 Feb;38(1):3-11. doi: 10.1111/j.1365-2710.2009.01087.x. Epub 2009 Aug 14.

PMID:
23281770
4.

Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors.

Strumberg D, Schultheis B, Traugott U, Vank C, Santel A, Keil O, Giese K, Kaufmann J, Drevs J.

Int J Clin Pharmacol Ther. 2012 Jan;50(1):76-8. No abstract available.

5.

Biomarkers in tumor angiogenesis and anti-angiogenic therapy.

Pircher A, Hilbe W, Heidegger I, Drevs J, Tichelli A, Medinger M.

Int J Mol Sci. 2011;12(10):7077-99. doi: 10.3390/ijms12107077. Epub 2011 Oct 21. Review.

6.

Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours.

Trarbach T, Schultheis B, Gauler TC, Schneider V, Strumberg D, Eberhardt WE, Le Scouiller S, Marotti M, Brown KH, Drevs J.

Invest New Drugs. 2012 Oct;30(5):1962-71. doi: 10.1007/s10637-011-9754-x. Epub 2011 Oct 12.

PMID:
21989836
7.

Liver cancer: Targeted future options.

Pircher A, Medinger M, Drevs J.

World J Hepatol. 2011 Feb 27;3(2):38-44. doi: 10.4254/wjh.v3.i2.38.

8.

Antitumor effect of the vascular-disrupting agent ZD6126 in a murine renal cell carcinoma model.

Medinger M, Esser N, Soltau J, Lehmann KM, Konerding MA, Wolloscheck T, Ryan AJ, Drevs J.

Int J Oncol. 2011 Feb;38(2):455-64. doi: 10.3892/ijo.2010.867. Epub 2010 Dec 7.

PMID:
21152862
9.

A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancer.

Drevs J, Medinger M, Mross K, Fuxius S, Hennig J, Buechert M, Thomas A, Unger C, Chen BL, Lebwohl D, Laurent D.

Anticancer Res. 2010 Jun;30(6):2335-9.

PMID:
20651389
10.

Antitumor and antiangiogenic activity of cediranib in a preclinical model of renal cell carcinoma.

Medinger M, Esser N, Zirrgiebel U, Ryan A, Jürgensmeier JM, Drevs J.

Anticancer Res. 2009 Dec;29(12):5065-76.

11.

Anti-tumor effects of AMT in the renal cell carcinoma model.

Caballero M, Scheele J, Zirrgiebel U, Esser N, Schächtele C, Soltau J, Rentschler J, Diergarten K, Drevs J.

Oncol Rep. 2010 Jan;23(1):205-10.

PMID:
19956883
12.

[Isolated lymph node metastasis in pericardial fat flap after bronchial stump coverage].

Fröhlich J, Rischke C, Rentschler J, Drevs J, Stremmel C, Passlick B.

Chirurg. 2010 Oct;81(10):930-2. doi: 10.1007/s00104-009-1839-0. German.

PMID:
19940968
13.

Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors.

Langenberg MH, van Herpen CM, De Bono J, Schellens JH, Unger C, Hoekman K, Blum HE, Fiedler W, Drevs J, Le Maulf F, Fielding A, Robertson J, Voest EE.

J Clin Oncol. 2009 Dec 20;27(36):6152-9. doi: 10.1200/JCO.2009.22.2273. Epub 2009 Nov 9.

PMID:
19901116
15.

Mode of action and clinical impact of VEGF signaling inhibitors.

Soltau J, Drevs J.

Expert Rev Anticancer Ther. 2009 May;9(5):649-62. doi: 10.1586/era.09.19. Review.

PMID:
19445581
16.

AMT: preclinical pharmacology studies.

Niazi F, Drevs J, Diergarten K, Dorn A, Maier A, Fiebig HH, Bruyns E, Scheele J.

Int J Oncol. 2009 May;34(5):1341-52.

PMID:
19360346
17.

Molecular targeted therapies for solid tumors: management of side effects.

Grünwald V, Soltau J, Ivanyi P, Rentschler J, Reuter C, Drevs J.

Onkologie. 2009 Mar;32(3):129-38. doi: 10.1159/000194949. Epub 2009 Feb 16. Review.

PMID:
19295254
18.

Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma.

Doehn C, Esser N, Pauels HG, Kiessig ST, Stelljes M, Grossmann A, Jocham D, Drevs J.

Eur Urol. 2009 Jul;56(1):123-31. doi: 10.1016/j.eururo.2008.05.034. Epub 2008 Jun 4.

PMID:
18550267
19.

Antitumoral and antiangiogenic efficacy of bisphosphonates in vitro and in a murine RENCA model.

Soltau J, Zirrgiebel U, Esser N, Schächtele C, Totzke F, Unger C, Merfort I, Drevs J.

Anticancer Res. 2008 Mar-Apr;28(2A):933-41.

20.

VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: relationship to retinopathy of prematurity.

Pieh C, Agostini H, Buschbeck C, Krüger M, Schulte-Mönting J, Zirrgiebel U, Drevs J, Lagrèze WA.

Br J Ophthalmol. 2008 May;92(5):689-93. doi: 10.1136/bjo.2007.128371. Epub 2008 Apr 11.

PMID:
18408080
21.

Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients--results of a phase II study.

Steinbild S, Arends J, Medinger M, Häring B, Frost A, Drevs J, Unger C, Strecker R, Hennig J, Mross K.

Onkologie. 2007 Dec;30(12):629-35. Epub 2007 Nov 30.

PMID:
18063875
22.

Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin.

Unger C, Häring B, Medinger M, Drevs J, Steinbild S, Kratz F, Mross K.

Clin Cancer Res. 2007 Aug 15;13(16):4858-66.

23.

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors.

Drevs J, Siegert P, Medinger M, Mross K, Strecker R, Zirrgiebel U, Harder J, Blum H, Robertson J, Jürgensmeier JM, Puchalski TA, Young H, Saunders O, Unger C.

J Clin Oncol. 2007 Jul 20;25(21):3045-54.

PMID:
17634482
25.

Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen.

Kratz F, Mansour A, Soltau J, Warnecke A, Fichtner I, Unger C, Drevs J.

Arch Pharm (Weinheim). 2005 Oct;338(10):462-72.

PMID:
16211657
26.

Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.

Lee L, Sharma S, Morgan B, Allegrini P, Schnell C, Brueggen J, Cozens R, Horsfield M, Guenther C, Steward WP, Drevs J, Lebwohl D, Wood J, McSheehy PM.

Cancer Chemother Pharmacol. 2006 Jun;57(6):761-71. Epub 2005 Sep 20.

PMID:
16172907
27.

Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours.

Mross K, Drevs J, Müller M, Medinger M, Marmé D, Hennig J, Morgan B, Lebwohl D, Masson E, Ho YY, Günther C, Laurent D, Unger C.

Eur J Cancer. 2005 Jun;41(9):1291-9.

PMID:
15939265
28.

The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma.

Drevs J, Konerding MA, Wolloscheck T, Wedge SR, Ryan AJ, Ogilvie DJ, Esser N.

Angiogenesis. 2004;7(4):347-54. Epub 2005 May 9.

PMID:
15886878
29.

Receptor tyrosine kinases and anticancer therapy.

Medinger M, Drevs J.

Curr Pharm Des. 2005;11(9):1139-49. Review.

PMID:
15853662
30.

Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials.

Drevs J, Zirrgiebel U, Schmidt-Gersbach CI, Mross K, Medinger M, Lee L, Pinheiro J, Wood J, Thomas AL, Unger C, Henry A, Steward WP, Laurent D, Lebwohl D, Dugan M, Marmé D.

Ann Oncol. 2005 Apr;16(4):558-65. Epub 2005 Feb 10.

31.

Intravitreal injection of specific receptor tyrosine kinase inhibitor PTK787/ZK222 584 improves ischemia-induced retinopathy in mice.

Maier P, Unsoeld AS, Junker B, Martin G, Drevs J, Hansen LL, Agostini HT.

Graefes Arch Clin Exp Ophthalmol. 2005 Jun;243(6):593-600. Epub 2005 Jan 14.

PMID:
15650859
32.

Plasma vascular endothelial growth factor and serum soluble angiopoietin receptor sTIE-2 in patients with dural arteriovenous fistulas: a pilot study.

Klisch J, Kubalek R, Scheufler KM, Zirrgiebel U, Drevs J, Schumacher M.

Neuroradiology. 2005 Jan;47(1):10-7. Epub 2005 Jan 14.

PMID:
15650831
33.

Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study.

Mross K, Niemann B, Massing U, Drevs J, Unger C, Bhamra R, Swenson CE.

Cancer Chemother Pharmacol. 2004 Dec;54(6):514-24. Epub 2004 Aug 21.

PMID:
15322827
34.

Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.

Drevs J, Fakler J, Eisele S, Medinger M, Bing G, Esser N, Marmé D, Unger C.

Anticancer Res. 2004 May-Jun;24(3a):1759-63.

35.

[Treatment with bisphosphonates].

Drevs J.

Med Monatsschr Pharm. 2004 Jun;27(6):208. German. No abstract available.

PMID:
15230520
36.

ZD-6126 AstraZeneca.

Soltau J, Drevs J.

IDrugs. 2004 Apr;7(4):380-7. Review.

PMID:
15057644
37.

Angiogenesis and the ET-1/ETA receptor system: immunohistochemical expression analysis in bone metastases from patients with different primary tumors.

Medinger M, Adler CP, Schmidt-Gersbach C, Soltau J, Droll A, Unger C, Drevs J.

Angiogenesis. 2003;6(3):225-31.

PMID:
15041798
38.

[Receptor tyrosine kinases. A target for new cancer treatments].

Medinger M, Soltau J, Unger C, Drevs J.

Med Monatsschr Pharm. 2004 Feb;27(2):50-8; quiz 59-60. Review. German. No abstract available.

PMID:
15008274
39.

Antiangiogenic potency of FK866/K22.175, a new inhibitor of intracellular NAD biosynthesis, in murine renal cell carcinoma.

Drevs J, Löser R, Rattel B, Esser N.

Anticancer Res. 2003 Nov-Dec;23(6C):4853-8.

PMID:
14981935
40.

[Bisphosphonates in oncology].

Soltau J, Medinger M, Unger C, Drevs J.

Med Monatsschr Pharm. 2003 Dec;26(12):411-7. Review. German. No abstract available.

PMID:
14699777
41.

DCE-MRI in clinical trials: data acquisition techniques and analysis methods.

Strecker R, Scheffler K, Büchert M, Mross K, Drevs J, Hennig J.

Int J Clin Pharmacol Ther. 2003 Dec;41(12):603-5. Review. No abstract available.

PMID:
14692712
42.

Surrogate marker in clinical studies with anti-angiogenic drugs.

Zirrgiebel U, Drevs J.

Int J Clin Pharmacol Ther. 2003 Dec;41(12):600-2. Review. No abstract available.

PMID:
14692711
43.

Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies.

Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, Horsfield MA, Mross K, Ball HA, Lee L, Mietlowski W, Fuxuis S, Unger C, O'Byrne K, Henry A, Cherryman GR, Laurent D, Dugan M, Marmé D, Steward WP.

J Clin Oncol. 2003 Nov 1;21(21):3955-64. Epub 2003 Sep 29.

PMID:
14517187
44.

PTK/ZK (Novartis).

Drevs J.

IDrugs. 2003 Aug;6(8):787-94. Review.

PMID:
12917775
45.

A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2.

Mansour AM, Drevs J, Esser N, Hamada FM, Badary OA, Unger C, Fichtner I, Kratz F.

Cancer Res. 2003 Jul 15;63(14):4062-6.

46.

Soluble markers for the detection of hypoxia under antiangiogenic treatment.

Drevs J.

Anticancer Res. 2003 Mar-Apr;23(2A):1159-61. Review.

PMID:
12820365
47.

Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584.

Thomas AL, Morgan B, Drevs J, Unger C, Wiedenmann B, Vanhoefer U, Laurent D, Dugan M, Steward WP.

Semin Oncol. 2003 Jun;30(3 Suppl 6):32-8. Review.

PMID:
12802793
48.

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours.

Eskens FA, Dumez H, Hoekstra R, Perschl A, Brindley C, Böttcher S, Wynendaele W, Drevs J, Verweij J, van Oosterom AT.

Eur J Cancer. 2003 May;39(7):917-26.

PMID:
12706360
49.

Antiangiogenesis: current clinical data and future perspectives.

Drevs J, Laus C, Medinger M, Schmidt-Gersbach C, Unger C.

Onkologie. 2002 Dec;25(6):520-7. Review.

PMID:
12566896
50.

Receptor tyrosine kinases: the main targets for new anticancer therapy.

Drevs J, Medinger M, Schmidt-Gersbach C, Weber R, Unger C.

Curr Drug Targets. 2003 Feb;4(2):113-21. Review.

PMID:
12558064

Supplemental Content

Support Center